About Heidelberg Pharma AG

Company Description

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. The Company was founded in September 1997 by a team of physicians and oncologists from the Technical University of Munich. In 2000, the Company changed to an AG from a GmbH legal structure. In 2011, the subsidiary Heidelberg Pharma Research GmbH was acquired.
Heidelberg Pharma was restructured in 2014, which led to the discontinuation of all research and development activities in Munich. The shareholder’s meeting in July 2017 decided to move the registered office of WILEX AG from Munich to Ladenburg and to change the name of the Company to Heidelberg Pharma AG. The subsidiary Heidelberg Pharma GmbH is now named Heidelberg Pharma Research GmbH.

Year founded

1997

Served area

Worldwide

Headcount

96

Headquarters

Gregor-Mendel-Straße 22, 68526 Ladenburg – Germany

Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume Average price
07.09.22 Plate, Achim Board Buy 30,869.92 € 07.09.22
06.09.22 Kudlek, Dr. Birgit Supervisory board Other 7,496.16 € 06.09.22
22.03.22 4H invest GmbH Close relation Other 0.00 € 22.03.22
22.03.22 Bohlini invest GmbH Close relation Other 0.00 € 22.03.22
16.03.22 WAOW entrepreneurship GmbH Close relation Buy 494,208.00 € 16.03.22
16.03.22 Beretti, Giulio Other Buy 4,025.00 € 16.03.22
22.02.22 MH-LT-Investments GmbH Close relation Other 0.00 € 22.02.22
18.02.22 Riedel, Oliver Board Buy 16,122.00 € 18.02.22
18.02.22 Riedel, Oliver Board Buy 9,555.00 € 18.02.22
17.02.22 Weng, Rüdiger K. Board Buy 14,500.00 € 17.02.22
29.07.21 Schmidt-Brand, Dr. Jan Board Other 0.00 € 29.07.21
29.07.21 Pahl, Prof. Dr. Andreas Board Other 0.00 € 29.07.21

Shareholder information

Shares outstanding

34,175,809

IPO

Nov. 13, 2006

Designated Sponsor(s)

Stifel Europe Bank AG, Pareto Securities

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.